Human TWEAK/TNFSF12 Affinity Purified Polyclonal Ab (25 UG)【科瑞奥博】

产品中心

当前位置：首页>产品中心

Human TWEAK/TNFSF12 Affinity Purified Polyclonal Ab (25 UG)

货号： AF1090-SP 基本售价： 1378.1 元规格： -

产品信息

概述
货号	AF1090-SP
别名	APO3 ligand; APO3LMGC20669; DR3LGTWEAKAPO3/DR3 ligand; MGC129581; TNF-related weak inducer of apoptosis; TNFSF12; tumor necrosis factor (ligand) superfamily, member 12; tumor necrosis factor ligand superfamily member 12
全称	TNF-like and Weak Inducer of Apoptosis
反应种属	Human
应用	Western Blot(0.1 µg/mL) Immunocytochemistry(5-15 µg/mL)
目标/特异性	Detects human TWEAK in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant human (rh) BAFF, rhFas Ligand, rhGITR Ligand, rhOX40 Ligand, rhTRAIL and less than 1% cross-reactivity with rhAPRIL, rhLIGHT, rhTNF-alpha, rhVEGI, and rhTRANCE is observed.
使用方法	Western Blot: 0.1 µg/mL Immunocytochemistry: 5-15 µg/mL Neutralization: Measured by its ability to neutralize TWEAK/TNFSF12-induced inhibition of proliferation in the HT‑29 human colon adenocarcinoma cell line. Yu, K. Y. et al. (1999) J. Biol. Chem. 274:13733; Harrop, J. A. et al. (1998) J. Biol. Chem. 273:27548The Neutralization Dose (ND₅₀) is typically 2-8 µg/mL in the presence of 1 µg/mL Recombinant Human TWEAK/TNFSF12.
来源	Polyclonal Goat IgG
产品组分

性能
供应商	R&D Systems
Entrez Gene IDs	8742 (Human); 21944 (Mouse); 360548 (Rat)
应用文献
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier. Authors: Stephan D, Sbai O, Wen J, Couraud P, Putterman C, Khrestchatisky M, Desplat-Jego S J Neuroinflammation, 2013;10(0):9. Species: Human Sample Type: Cell Lysate Application: WB Potent anti-tumor killing activity of the multifunctional Treg cell line HOZOT against human tumors with diverse origins. Authors: Inoue T, Tashiro Y, Takeuchi M Int. J. Oncol., 2011;38(5):1299-306. Species: Human Sample Type: Whole Cells Application: Neut Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Authors: Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, Blanco-Colio LM, Meilhac O Arterioscler. Thromb. Vasc. Biol., 2010;30(6):1253-62. Species: Human Sample Type: Cell Culture Supernates Application: WB
纯化方式	Antigen Affinity-purified
免疫原	E. coli-derived recombinant human TWEAK Arg93-His249 Accession # Q4ACW9
内毒素水平	<0.10 EU per 1 μg of the antibody by the LAL method.
生物活性	Human
标记	Unconjugated
溶解方法	Reconstitute at 0.2 mg/mL in sterile PBS.
背景	TWEAK is a type II transmembrane protein belonging to the TNF superfamily (1). It contains a short cytoplasmic domain (amino acids (aa) 1-18), the transmembrane domain (aa 19-42) and an extracellular domain (aa 43-249). The extracellular domains of human and murine TWEAK share 89% aa sequence identity. A soluble form of TWEAK is generated from the membrane-associated molecules by proteolytic cleavage after Arg 93 suggesting that TWEAK may have long-range effects. TWEAK is expressed widely in many tissues and cells. At least two receptors that bind TWEAK have been identified (2-4). Death Receptor 3 (DR3), also known as TNFRSF12, Apo-3, LARD, WSL-1, or TRAMP, is a TNF receptor superfamily member that is expressed predominantly in tissues with high lymphocyte content (2). It has been suggested that induction of cell death by TWEAK-DR3 interaction involves the activation of NF-kappa B. In cells that lack DR3, alternate pathways of TWEAK-induced cell death mediated by receptors distinct from DR3 have been suggested (5, 6). TWEAK receptor (TWEAKR, alternatively known as FN14), is a novel TNF receptor superfamily member that also binds TWEAK (3, 4). It is a mitogen-inducible gene that is expressed in fibroblasts, hepetocellular carcinomas and endothelial cells. TWEAK-TWEAKR interaction has been shown to play a role in endothelial cell growth and migration. This effect of TWEAK is not mediated by an up-regulation of VEGF (7).
运输条件	Blue Ice
存放说明	4℃
参考文献	Chicheportiche, Y. et al. (1997) J. Biol Chem. 272:32401. Marsters, S. et al. (1998) Current Biol. 8:525. Wiley, S.R. et al. (2001) Immunity, 15:837. Feng, S-L.Y. et al. (2000) Am J. Path. 156:1253. Nakayama, M. et al. (2002) J. Immunol. 168:734. Schneider, P. et al. (1999) Eur. J. Immunol., 29:1785. Lynch, C. et al. (1998) J. Biol. Chem. 274:8455.

参考图片

TWEAK/TNFSF12 Inhibition of Cell Proliferation and Neutralization by Human TWEAK/TNFSF12 Antibody. Recombinant Human TWEAK/TNFSF12 (Catalog # 1090-TW) inhibits proliferation in the the HT‑29 human colon adenocarcinoma cell line in a dose-dependent manner (orange line). Activity elicited by Recombinant Human TWEAK/TNFSF12 (1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TWEAK/
TNFSF12 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1090). The ND₅₀ is typically 2-8 µg/mL.

TWEAK/TNFSF12 in MDA-MB-231 Human Cell Line. TWEAK/TNFSF12 was detected in immersion fixed MDA-MB-231 human breast cancer cell line using 10 µg/mL Goat Anti-Human TWEAK/TNFSF12 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1090) for 3 hours at room temperature. Cells were stained with the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.